Business Description
Founded in 2000 and headquartered in Melbourne, Amplia Therapeutics is an Australian company working to develop new medicines that target a protein involved in cancer growth and scarring of internal organs. Its lead drug candidate, Narmafotinib, is currently being tested in clinical trials for pancreatic cancer, ovarian cancer, and a serious lung condition called idiopathic pulmonary fibrosis. The company is also advancing a second compound, AMP886, aimed at treating additional cancer and fibrosis-related diseases.
